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Abstract. To examine the role of renal excretory 
function for erythropoietin (EPO) formation we have 
determined the kinetics of plasma immunoreactive 
EPO (irEPO) in patients with end-stage renal disease 
undergoing renal allotransplantation (RTX). 
In 13 patients with immediate excretory graft func-
tion (imGF) and stable haemoglobin (Hb) concentra-
tions (median Hb 9-5 g dl ~ 1 and median irEPO 18 mU 
m l - 1 before RTX) irEPO increased significantly on 
day 4 after RTX to a median value of 29 mU ml~1 and 
2 days later reached a plateau of 34-4±3-3 mU m l - 1 
(mean ± SD of daily median values during days 6-20). 
In patients with imGF having acute blood loss and 
subsequently receiving transfusions, irEPO responded 
in an inverse fashion to changes in Hb concentrations. 
In 12 patients with delayed graft function (dGF) 
(median Hb8-8gdl 1 and median irEPO ISmUml" 1 
before RTX) irEPO levels during the period of excre-
tory failure remained either unchanged or displayed 
marked variations with peak values greatly exceeding 
those of patients with imGF. These variations were not 
related to changes in Hb concentrations and irEPO 
levels did not change following alterations in Hb 
concentrations. Upon recovery of excretory function 
irEPO approached the values found in patients with 
imGF. 
The results suggest that an intact excretory renal 
function is not a prerequisite for the capability to 
produce EPO, but correlates with the oxygen-depen-
dent regulation of EPO formation. 
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Introduction 
Patients suffering from end-stage renal disease 
(ESRD) generally develop an anaemia that results 
predominantly from inappropriately low erythropoie-
tin (EPO) production by the damaged kidneys [1,2]. 
The physiological mechanisms underlying EPO for-
mation and their possible alterations during kidney 
disease are not yet determined. In particular, it is not 
known whether the inappropriate EPO formation 
during ESRD results from destruction of the EPO-
producing cells or functional alterations accompany-
ing excretory renal failure. Recent observations in 
acute renal failure suggest that EPO formation may be 
impaired when there is functional failure but no 
chronic structural damage to the kidney [3,4]. To 
further elucidate the role of excretory renal function 
for the biosynthesis of EPO, we decided to study the 
relationship between EPO formation and renal excre-
tory function in renal allograft recipients, in whom 
functioning grafts displayed a temporary delay in the 
onset of excretory function. 
Previous studies addressing the correction of anae-
mia after renal transplantation (RTX), have shown 
that increases in EPO levels precede the reticulocytosis 
and rise in haematocrit following RTX [5,6,7] and in 
some cases EPO rose as early as the first to third post-
transplant day [5,7]. An investigation by Besarab et al. 
[6] includes some data on EPO formation in a sub-
group of patients with delayed graft function. While 
EPO did generally not increase until excretory graft 
function commenced, increments in some patients 
appeared to be related to differences in immunosup-
pressive regimens. However, in these patients, EPO 
values were not related to haemoglobin concentrations 
and sampling intervals were at least 3 days. Further-
more, a very recent study reports on a biphasic increase 
in EPO, with a first increase that was independent of 
graft function [8]. 
In the present investigation we determined plasma 
immunoreactive EPO (irEPO), haemoglobin and 
serum creatinine concentrations daily for at least 3 
weeks following RTX in patients under standardized 
immunosuppressive therapy, and compared the time 
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course and magnitude of increases in irEPO in patients 
with immediate graft (imGF) function with that in 
patients with delayed graft function (dGF). 
Patients and methods 
Patients 
A total of 27 consenting patients who underwent renal 
transplantation during two study periods were 
included in this investigation. Patient characteristics 
and the underlying renal disease are given in Table 1. 
None of the patients had received transfusions at least 
3 months before RTX or had been treated with 
recombinant EPO. According to excretory graft func-
tion, patients were divided into two groups with 
immediate and delayed graft function, respectively. 
ImGF was considered present if (1) serum creatinine 
values declined continuously and approximately expo-
nentially after RTX, and (2) reached values less than 
300 fimol l - 1 within, maximally, 7 days (n= 15). 
Table 1. Clinical details of grafted patients studied 
Cause of renal Age Months 
Patient failure Sex (years) on HD 
(a) Immediate graft function 
1 glomerulonephritis m 56 11 
2 glomerulonephritis m 48 81 
3 pyelonephritis m 20 8 
4 A D P K D f 51 21 
5 interstitial nephr. f 56 41 
6 pyelonephritis and m 23 16 
unilat. renal 
hypoplasia 
7 pyelonephritis, VUR m 48 171 
8 glomerulonephritis m 54 49 
9 nephrosclerosis and m 63 23 
urate nephropathy 
10 IgA nephropathy m 31 11 
11 pyelonephritis m 17 18 
12 urate nephropathy m 62 79 
13 glomerulonephritis m 67 34 
14 nephrosclerosis m 62 12 
15 glomerulonephritis m 48 54 
(b) Delayed graft function 
16 unknown f 26 12 
17 glomerulonephritis m 51 106 
18 focal sclerosis m 49 95 
19 glomerulonephritis m 27 64 
20 renal dysplasia m 23 34 
21 diabetic nephropathy m 48 11 
22 diabetic nephropathy m 51 34 
23 glomerulonephritis f 30 100 
24 focal sclerosis m 42 103 
25 pyelonephritis, VUR m 32 108 
26 glomerulonephritis m 41 39 
27 nephrocalcinosis 
(urogen. tuberculosis) f 44 84 
HD, hemodialysis; A D P K D , autosomal dominant polycystic 
kidney disease; VUR vesicoureteric reflux. 
All patients received the first transplant except patients no. 16, 18 
20 (second transplant) and 23 (fourth transplant). Patients no 3 and 
11 received live-related grafts. 
Patients were grouped as having dGF when serum 
creatinine values (1) either did not decline sponta-
neously after RTX so that temporary continuation of 
haemodialysis was required (w8) or the decline in 
creatinine levels was protracted (n = 4), and (2) serum 
creatinine values less than 300 fimol l - 1 were reached 
within 30 days post-RTX. Patients who did not meet 
the criteria of one of the two groups either because 
graft failure was prolonged or irreversible (n = 5) or 
worsening of graft function occurred after serum 
creatinine levels of 300 pmo\ l _ i had been reached 
(« = 7), were not included. 
In all patients included, warm ischaemia time of 
grafts was less than 7 min; cold ischaemia time was 
1420 (1252-1533) min and 1718 (1476-2145) min 
(median and interquartile range) in patients with 
imGF and dGF, respectively. 
Immunosuppressive therapy 
Standardized immunosuppressive therapy consisted of 
cyclosporine A (10 mg k g - 1 day ~~ 1 started immediately 
post-transplantation and dose later adjusted to achieve 
serum levels of 200-300 ng ml"1) and steroids (500 mg, 
250 mg and 100 mg methylprednisolone on days 0, 1 
and 2, and 1 mg prednisolone kg' 1 day - 1 started on 
post-transplant day 3 and reduced daily by 0-1 mg kg - 1 
day - 1 during the initial 7 days, and then by 2-5 mg 
every 14 days to a maintenance dose of 7-5 mg day -1). 
Additionally, azathioprine (2 mg kg - 1 ) was given to 
patients with acute graft rejection or those on high 
immunological risk, i.e. with preformed cytotoxic 
antibodies or rejection of previous grafts. 
Additional drug treatment 
All patients were on antacids and local antimycotic 
agents. Other drugs were calcium antagonists, beta-
blocking agents or converting enzyme inhibitors for 
treatment of hypertension and loop diuretics if 
required. 
Peripheral venous blood was withdrawn from all 
patients before RTX and daily between 08.00 and 
10-00 for at least 3 weeks and up to 56 days following 
RTX, for determinations of plasma irEPO concentra-
tions, serum creatinine and haemoglobin concentra-
tions. 
Measurement of erythropoietin 
EPO was measured in heparinized plasma samples by 
radioimmunoassay as described previously [9]. In 
brief, 100-jul samples plus 20 fi\ of 30% bovine serum 
albumin were incubated for 24 h with 100 ß\ rabbit 
antiserum raised against pure recombinant human 
EPO. One-hundred p\ of (125I) iodotyrosyl-EPO 
(8xl0~" mol Amersham International, Amer-
sham, UK) were then added and after an additional 
incubation period of 24 h separation of free and bound 
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ligand was carried out using a second antibody 
technique. The second International Reference Prep-
aration of human urinary EPO (WHO) was used as 
standard. The lower detection limit of the assay is 5 mu 
m l - \ the interassay coefficient of variation is 6-7% for 
a sample containing 44-2 + 30 mu irEPO m l - 1 
(mean + SD). Geometric mean EPO level for non-
anaemic adults is 17-9muml_l (95% range from 11-31 
mu ml"1; n~$4). 
Serum creatinine levels and haemaglobin concentrations 
These were determined by routine laboratory methods. 
Statistics 
Unless otherwise indicated, data are presented as 
median and interquartile range (in brackets). Mann-
Whitney test and Wilcoxon signed-rank test were used 
to compare median values of unpaired and paired 
observations, respectively. Student's unpaired Mest 
was used to compare mean values. A P value <005 
was considered significant. 
Results 
Patients with imGF 
EPO formation was analysed separately in two 
patients experiencing marked changes in haemoglobin 
concentrations in the post-transplant phase and in the 
remaining patients with stable haemoglobin (n= 13). 
Figure 1 shows the time-course of plasma irEPO levels 
following RTX in these latter 13 patients with imGF in 
relation to serum creatinine and haemoglobin concen-
trations. Parallel to the decline in serum creatinine 
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Figure 1. Temporal pattern of serum creatinine (upper), haemoglobin (middle) and plasma irEPO (lower) concentrations in 
patients with imGF after RTX. Data are median values and interquartile range in 13 patients studied from days 0 to 20 and in 
seven of these patients additionaly studied between weeks 4 and 11. For comparison, interquartile range and 95% range of serum 
irEPO in healthy adults is included (stippled). Following RTX EPO levels were first significantly elevated on post-transplant day 4 
(P<002). 
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values, median irEPO level increased significantly 
from 18 (14-25) mU m l - 1 to 29 (22-38) m U m l " 1 on 
post-transplant day 4 (P < 0 02) and on day 6 reached a 
plateau of 34-4 + 3-3 m U ml (mean + SD of daily 
median values on days 6-20). During the first three 
post-transplant weeks none of these patients exhibited 
any variation in haemoglobin concentrations greater 
than 2-2 g d l _ 1 or received transfusions. In seven of 
these patients i rEPO and haemoglobin concentrations 
were further determined weekly up to week 8 following 
R T X , and between weeks 9 and 11. i rEPO values were 
31-3 + 3-7 m U m l - 1 (mean + SD of weekly median 
values) between weeks 4 and 8, and median i rEPO level 
was 25 (18-49) m U m l - 1 between weeks 9 and 11. 
Haemoglobin concentrations increased continuously 
from 10-3 (9-3-11-2) g d l " 1 in week 4 to 121 (11-6 ' 
12-7) g d l " 1 between weeks 9 and 11 (Fig. 1). ! 
Two additional patients with i m G F (no., 14, 15; 
Table 1) experienced a temporal marked decline in 
haemoglobin concentrations between post-transplant 
days 29 and 35, and 14 and 33, respectively. Both 
patients showed significant increases in their i rEPO 
levels during these periods. In one patient (no. 14) in 
whom the haemoglobin concentration fell from 9 to 
5-6 g d l _ 1 due to wound bleeding, and subsequently 
rose to 10-2 g d l " 1 following surgical revision and 
transfusion, i rEPO values increased from a median 
value of 31 -5 (28-38) m U ml ~ 1 before blood loss (days 
20 30 40 
Time after RTX (days) 
50 
Figure 2. Time-course of serum creatinine (upper), haemoglobin (middle) and plasma i rEPO (lower) concentrations in a patient 
experiencing acute blood loss due to gastrointestinal bleeding and subsequently receiving transfusion of two units of erythrocytes 
on day 31 following R T X (arrow). 
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4-29) to a median value of 88 (71-114) m U m l - ' 
during the reduction in haemoglobin concentrations, 
and after transfusion declined again to a median value 
of 15 5 (11-17) m U m l " 1 . The time-course of EPO 
levels in relation to haemoglobin for the other patient 
(no. 15) is depicted in Fig. 2. Parallel to the reduction in 
haemoglobin concentrations due to gastrointestinal 
bleeding, i rEPO increased to a median value of 130 
(107-133) m U m l " 1 . 
Patients with dGF 
In patients with delayed graft function, EPO forma-
tion following R T X was much more variable. The 
temporal pattern of plasma i rEPO levels and haemo-
globin concentrations in the whole group of 12 patients 
with d G F , during the time-period when serum creati-
nine concentrations were higher than 300 fimo\ l - 1 , is 
illustrated in Fig. 3. For comparison, interquartile 
range (dark stippled) and absolute range (light stip-
pled) of values in patients with i m G F is included. Pre-
transplant i rEPO was not significantly different in both 
groups (P>0T5). During the phase of excretory 
failure, median EPO values in patients with d G F 
increased only slightly from 15 (12™18) mu m l " 1 to 
22-7 ± 5 mU m l " 1 ( m e a n ± S D of daily median values 
between days 4 and 24; P<0001 vs. patients with 
imGF) and were generally below the lower quartile of 
those in patients with imGF. However, irrespective of 
the lower median i rEPO levels, the absolute range of 
i rEPO levels in patients with d G F was considerably 
higher, and maximum values in these patients mar-
kedly exceeded those during imGF. The lower median 
EPO values were obviously not due to higher erythro-
cyte mass, since haemoglobin concentrations were 
even slightly below those in patients with i m G F 
(8-7 ± 0-7 g d l " 1 vs. 9-7 ± 0-6 g d l " 1 ; mean ± SD of daily 
median values; P < 0-001). Furthermore, except 
patient no. 16 (see below) none of the patients with 
d G F was transfused. 
Analysis of the time-course of i rEPO levels in 
individual patients with d G F revealed two typical 
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Figure 3. Temporal pattern of haemoglobin (upper) and plasma i r E P O (lower) concentrations in 12 patients with d G F , including 
only values during the phase of excretory graft failure (serum creatinine > 300 /miol I" 1). Values are median (filled circles) with 
interquartile range (solid bars) and absolute range (broken line). For comparison, interquartile range (dark stippled) and absolute 
range (light stippled) of plasma i rEPO in patients with i m G F is included. Except on days 7 9 and 11, median i rEPO in patients 
with d G F was not significantly different from pre-transplant values. On days. 4-6. 8 11. 14 and 20. median i rEPO in patients with 
d G F was significantly lower than in patients with i m G F . 
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Table 2. Graft function and i r E P O levels in patients with delayed graft function 
Plasma i r E P O (mU ml 
Patient no. 
Duration of 
excretory graft 
failure (days)* 
Haemodialysis 
After R T X 
Graft biopsy 
(days post R T X ) 
Before 
R T X 
Excretory graft failure 
(m in -media n-max) 
During Aftert 
(a) Patients with little change in irEPO during excretory graft failure 
16 40 yes ' slight R E J (9) 
20 34 yes A T N (4); slight R E J , 
vasculopathy (25) 
22 6 no not performed 
23 20 yes A T N , slight R E J (4) 
25 17 yes slight R E J (8) 
(b) 
17 
18 
Patients with transient elevations in irEPO during excretory graft failure 
19 
21 
24 
26 
27 
20 
28 
17 
7 
8 
11 
19 
yes 
yes 
yes 
no 
yes 
no 
no 
A T N (12) 
slight R E J , 
tubular necrosis, 
vasculopathy (10); 
R E J , vasculopathy (19) 
R E J 
not performed 
not performed 
not performed 
not performed 
15 
20 
9 
25 
12 
14 
14 
17 
12 
5 
34 
13—19—31 
9—19—27 
20—22—30 
8—12—25 
8—14—27 
18—35—213 
11—22—386 
10—33-127 
8—12—85 
7—22—68 
5-X5-57 
16—30—168 
26— 39—45 (15) 
not determined 
20—29—49(18) 
7/—20—25 (31) 
27— 36—45 (15) 
43-
29-
-53—66 (6) 
-38—6/ (22) 
21—31—43 (6) 
15—22—50 (16) 
20—31—40 (17) 
y?—19—32 (11) 
31—51—100 (23) 
*Days post R T X , during which serum creatinine values were above 300 /imol 1"'. 
t Numbers in parentheses are number of observations after excretory graft failure. 
R E J rejection; A T N , acute tubular necrosis. 
In patient no. 20 E P O determinations could not be continued because he was transferred to another hospital. 
patterns, according to which patients could be grouped 
(Table 2). Five patients (Nos 16, 20, 22 , 23 and 25) did 
not show any significant increase in i rEPO levels 
during the phase of excretory failure and no single 
value exceeded 31 m U m l - 1 , while the median pre-
transplant value was 18 ( 1 5 - 2 0 ) m U m l - 1 . A n increase 
in i rEPO into the range of values in patients with i m G F 
occurred, however, after excretory function had 
resumed (Table 2). Daily i rEPO values for one of these 
patients (no. 16) are illustrated in Fig. 4. During the 
first 4 0 post-transplant days there were only very slight 
changes in irEPO concentrations and an obvious 
increase of i rEPO was not observed until excretory 
graft function commenced. At that time i rEPO 
increased, even though haemoglobin concentrations 
due to blood transfusion were approximately 3 g dl ~ 1 
higher than during the early phase. 
In the remaining patients with d G F (nos 1 7 - 1 9 , 2 1 , 
24 , 26 & 27) irregular transient increases in i rEPO 
levels were observed during the period of excretory 
graft failure with peak levels up to 368 m U m l " 1 and 
baseline values that were not different from pre-
transplant levels (group B, Table 2). In these patients a 
sustained elevation in EPO was also found after the 
end of excretory graft failure and at the same time 
intra-individual variations became less pronounced 
(Table 2). Figure 5 demonstrates a typical example for 
this pattern of i rEPO levels (no. 18). It is apparent that 
the variations in i rEPO concentrations were not 
related to changes in haemoglobin concentration. 
With the onset of excretory function i rEPO levels 
approached the values found in patients with imGF. 
Individual duration of excretory graft failure and 
histological diagnosis in those patients biopsied are 
included in Table 2. Median cold ischemia time of 
grafts in patients with little change in i rEPO (group A ) 
was 2 0 3 0 min (range: 1 5 2 8 - 2 4 5 0 min) and slightly 
higher than in patients with transient elevations in 
i rEPO (group B) (median: 1645 min; range: 1 3 9 0 - 2 2 5 9 
min) ( jP<0-05) . Analysis of medication in patients 
with i m G F and d G F revealed no single drug or 
therapeutic scheme that was consistently associated 
with a specific pattern of EPO levels following R T X . 
As expected, additional immunosuppression with 
azathioprine had been mainly given to patients in the 
group with d G F (nos 1 6 - 1 8 , 2 0 - 2 3 , 25 and 27). 
However, application of azathioprine did not correlate 
with different time-courses of E P O levels in these 
patients and was also given to two graft recipients with 
i m G F (nos 1 and 2). Furosemide and calcium antago-
nists were also given to patients in both groups with 
different graft function (nos 4, 5, 7, 9, 11, 13, 16, 18, 19, 
2 1 - 2 4 , 26, and 27 and nos 4, 6, 7, 8, 11, 12, 14, 15, 18 ,21 
and 22 , respectively). Some patients received addi-
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Figure 4. Time-course of serum creatinine (upper), haemoglobin (middle) and plasma i r E P O (lower) concentrations in a patient 
with d G F (no. 16). During the first 40 days post-transplantation there was only very slight change in i rEPO levels despite 
continuously declining haemoglobin concentrations until day 28. and a subsequent rise in haemoglobin levels following 
transfusion of two units erythrocytes on day 29 (arrow). A n obvious increase in i rEPO occured only after day 40, when excretory 
era ft function had commenced. 
tional antihypertensive medication with ^-blocking 
agents (nos 11,18 and 23), Clonidine (nos 7, 17, 23 and 
26) or a converting enzyme inhibitor (no. 11). 
Discussion 
Before the availability of recombinant human EPO for 
replacement therapy, renal transplantation was vir-
tually the only way to correct the anaemia of end-stage 
renal disease. Early studies employing bioassays for 
EPO demonstrated that this correction of anaemia 
after R T X was frequently associated with an increase 
of EPO in graft recipients [10-12]. However, the low 
sensitivity of the bioassays available at that time made 
it difficult to precisely assess the pattern of E P O 
formation after R T X . Subsequent studies have shown 
that a rise in EPO may be detectable within 1 to 3 days 
following R T X when radioimmunoassays are being 
used [5-7]. The sensitivity of these immunoassays is 
about tenfold higher than that of bioassays and the 
validity of immunoassay determinations is confirmed 
by a close correlation of bioactivity and immunoreacti-
vity at higher concentrations of the hormone [9,13]. 
The present study indicates that the kinetics of 
i rEPO formation following R T X are variable, depend-
ing on the excretory function of the graft. In patients 
with imGF, EPO levels increased continuously after 
R T X and reached a plateau after about 1 week (Fig. 1). 
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Figure 5. Time course of serum creatinine (upper), haemoglobin (middle) and plasma i rEPO (lower) concentrations in a patient, in 
whom i rEPO levels showed marked variations during the phase of excretory graft failure (no. 18). A continuous increase in i rEPO 
alike in patients with i m G F , occured after day 28 when excretory graft function had commenced. 
This temporal pattern confirms qualitatively and 
extends two previous studies, also employing radioim-
munoassays, that demonstrated early increases of 
i rEPO after R T X [5,7], In contrast to Besarab et ai [7], 
who found a typically a fourfold increase in EPO 
within the first 2 post-transplant weeks, increases were 
less pronounced, and only about two- to threefold in 
our patients. This difference may be related to various 
factors, including individual haemoglobin concentra-
tions, immunosuppression and additional drug ther-
apy. More importantly, the questions arise if EPO 
formation following R T X is subject to oxygen-depen-
dent regulation and if the moderate increase in i rEPO 
of about 16 m U m l - 1 , observed in our patients, is 
appropriate in comparison with non-renal failure 
patients. According to the relationship between EPO 
levels and haematocrits or haemoglobin concentra-
tions established by Erslev et ai [14] and Cotes [13] for 
non-renal anaemias, the median EPO concentration of 
34 m U m l " 1 during the plateau phase would fit into the 
confidence limits for the actual haemoglobin concen-
tration, even though only one intact kidney contri-
butes to the rise in EPO. Also the increase in EPO in 
two patients having acute blood loss (Fig. 2) is well in 
accordance with the normal inverse exponential rela-
tionship between EPO and haemoglobin concentra-
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tions. In addition, the E P O formation in grafted 
kidneys tends to decline again once anaemia amelior-
ates [5,7,8,15] (Fig. 1), also indicating an intact 
regulation. Regarding the erythropoietic responsive-
ness to EPO, it remains nevertheless noteworthy, that 
after restoration of renal function a relatively slight 
increase in EPO levels is sufficient for the correction of 
renal anaemia. 
Taken together, the findings in patients with i m G F 
suggest a regulated EPO formation in grafted kidneys 
that parallels the onset of excretory function. Since 
transplants lack innervation and lymph drainage, two 
factors that have been implicated in EPO formation 
and secretion [16,17], neither appear to be essential for 
a regular increase of EPO levels. 
To assess the importance of excretory graft function 
for EPO formation, kinetics of EPO levels in patients 
with d G F (Figs 3-5; Table 2) can be compared with 
that in patients with imGF. During the phase of 
excretory failure we found no EPO formation in these 
patients that appeared to be regulated by haemoglobin 
concentrations. In some patients (group A , Table 2) 
EPO levels did not change at all in response to the pre-
existing anaemia or additional blood loss (Fig. 4). In 
others (group B, Table 2) marked variations of EPO 
were found that exceeded the values in patients with 
i m G F and were not related to changes in haemoglobin 
concentrations (Fig. 5). A comparatively high increase 
in EPO within the first week after R T X was recently 
also observed by Sun et ai [8], who averaged EPO 
levels in 31 transplant recipients. Although these 
investigators did not analyse their data separately 
according to different degrees of excretory graft func-
tion, the mean serum creatinine level in the whole 
group did not decline until day 10, suggesting that 
many of their patients would have met our criteria of 
d G F . 
Although we cannot definitely exclude the possibi-
lity that the native kidneys or the liver are responsible 
for some of the acute variations of circulating i rEPO in 
patients with d G F , several lines of indirect evidence 
suggest that these increased amounts of EPO are 
mainly derived from the grafted kidneys. First, in 
patients with E S R D , serum EPO values do not 
generally exceed the normal range of non-anaemic 
individuals [1,2], as was also obvious from the pre-
transplant values recorded in this investigation. Some 
variations in serum EPO in untransplanted patients 
have been observed in response to hypoxia [18,19], but 
these increases have not been of the extent seen in the 
present investigation. Second, the occurence of these 
spiking elevations was confined to periods of excretory 
graft failure and, third, was not associated with any 
specific type of underlying renal disease. In particular 
none of our patients in this group had polycystic 
kidneys, whereas Besarab et al. [7] found an early EPO 
peak in association with this disease. Experimental 
results in animals [20] and indirect evidence in humans 
[21] indicate that kidneys contain no stores for EPO, 
which could have been released, and it appears, 
therefore, that de novo synthesis of EPO in the grafted 
kidney was stimulated, apparently independent of 
blood oxygen-carrying capacity. From the data 
recorded in this study we were unable to define the 
nature of these stimuli. Both groups of patients, those 
without increase in EPO during excretory graft failure 
as well as those with transient elevations, comprised 
cases with different causes of graft failure and we found 
no association with the duration of graft failure or 
haemodialysis and drug treatment. The observation 
that in the group of patients with little increase in 
i rEPO the cold ischaemia time of the grafts was higher 
than in patients with temporary elevations in i rEPO, 
might indicate that EPO formation depends partially 
on the initial quality of the graft. Furthermore, among 
the possible determinants of EPO synthesis, direct 
drug effects on EPO-producing cells, e.g. effects of 
cyclosporins, as well as renal haemodynamic altera-
tions, tissue injury and release of inflammatory cytok-
ines, have to be considered. Although in the intact 
kidney reduction in arterial renal blood flow is only a 
minor stimulus for EPO formation [22], abnormal 
perfusion in kidneys with minimal excretory function or 
regional vasoconstriction may be of more significance. 
Irrespective of the cause, the transient high E P O 
concentrations in some patients indicate that the 
failure to adequately respond to the anaemia during 
excretory graft failure was not due to lack of ability to 
synthesize the hormone. Consequently it appears, 
rather that the oxygen dependent regulation of EPO is 
disturbed during excretory graft failure. Since the 
mechanisms underlying the physiologic regulation of 
EPO are poorly understood, the reason for this 
disturbance remains speculative as well. Thus it is 
possible that a local factor associated with the patho-
physiological derangements in the non-functioning 
graft inhibits the regulatory processes. Alternatively, 
the failure to adequately and continuously regulate 
EPO formation may indicate that ongoing excretory 
renal function is a prerequisite for the adaptation of 
EPO to changes in blood oxygen content. Although 
the cells producing EPO are probably not part of the 
nephron, but located in the cortical interstitium 
[23,24], experimental evidence indicates that the regu-
lation of EPO is related to tubular function [25] and 
this may account for the temporal concurrence 
between onset of excretory graft function and regu-
lated EPO formation in both groups of patients with 
d G F as well as in patients with imGF. 
In conclusion, we have shown that EPO formation 
after renal transplantation is related to excretory graft 
function. The onset of excretory graft function turned 
out not to be an absolute requirement for EPO 
production, but the oxygen-dependent regulation of 
EPO seems to operate only in the presence of excretory 
function. Regarding untransplanted patients with 
E S R D , this suggests that the lack of excretory function 
in their diseased kidneys may contribute to the 
572 K . - U . E C K A R D T et a/. 
inappropriately low E P O formation that accounts for 
the development of renal anaemia. 
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